OncoMatch

OncoMatch/Clinical Trials/NCT05366179

Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc

Is NCT05366179 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies CAR.B7-H3T cells infusion for glioblastoma multiforme.

Phase 1RecruitingUNC Lineberger Comprehensive Cancer CenterNCT05366179Data as of May 2026

Treatment: CAR.B7-H3T cells infusionThe purpose of this study is to test the safety of using T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (CAR.B7-H3T cells) in patients with glioblastoma. CAR.B7-H3T cells treatment has not been tested in humans and is not an approved treatment by the Food and Drug Administration for glioblastoma.

Check if I qualify

Extracted eligibility criteria

Cancer type

Glioblastoma

Prior therapy

Must have received: radiation therapy

Must have undergone at least 4005 cGy of radiation with concurrent temozolomide.

Must have received: cytotoxic chemotherapy (temozolomide) — concurrent with radiation

Must have undergone at least 4005 cGy of radiation with concurrent temozolomide.

Must have received: — surgery or biopsy at initial diagnosis

Must have previously undergone resection or biopsy at initial diagnosis.

Cannot have received: antiangiogenic agent (bevacizumab)

No current or previous exposure to antiangiogenic agents, such as bevacizumab.

Cannot have received: chimeric antigen receptor T cell therapy

Prior exposure to chimeric antigen receptor T cell therapy for treatment of glioblastoma.

Cannot have received: (carmustine wafers)

Previously implanted carmustine wafers or brachytherapy for the treatment of glioma.

Cannot have received: brachytherapy

Previously implanted carmustine wafers or brachytherapy for the treatment of glioma.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify